TIL's unique qualities include single treatment, no maintenance or follow-up therapy, and broad-spectrum antigen specificity ideally suited for many solid tumor cancers.

ADVANCING IMMUNO-ONCOLOGY

IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)

CLINICAL TRIALS

IOVANCE is conducting five Phase 2 clinical trials to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes for treatment of patients with Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer.

C-144-01 is a multicenter clinical trial for patients with Metastatic Melanoma at various sites in the US and Europe.

C-145-03 is a multicenter clinical trial now recruiting patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at various sites in the US.

IOV-LUN-201 is a multicenter clinical trial now recruiting patients with Non-Small Cell Lung Cancer (NSCLC) at various sites in the US.

C-145-04 is a multicenter clinical trial now recruiting patients with Cervical Carcinoma at various sites in the US and Europe.

IOV-COM-202 is a multicenter clinical trial now recruiting patients with Solid Tumors at various sites in the US.